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Two Randomised and Placebo-controlled Studies of an Oral Prostacyclin
Analogue (Iloprost) in Severe Leg Ischaemia
The Oral Iloprost in Severe Leg Ischaemia Study Group∗
(For list of individual participants, steering committee, sponsor and address for correspondence, please see Addendum)
Two separate studies are described using the same prostacyclin analogue in a similar group of patients.
Objectives: to assess the tolerability and efficacy of two dose regimens of oral Iloprost compared with placebo in the
treatment of patients with ischaemic ulcers, gangrene or rest pain due to severe arterial disease over a period of 4 weeks
(Study A) and one year (Study B).
Design: multicentre, placebo controlled, double-blind, randomized prospective studies.
Subjects & Methods: 178 (study A) and 624 (study B) patients with trophic skin lesions (ulcers or gangrene) or
ischaemic rest pain due to severe arterial disease. To confirm severe arterial disease patients were required to have a
systolic ankle Doppler pressure of 70 mmHg or less or a toe systolic Doppler pressure of 50 mmHg or less in one leg.
In both studies patients were randomly allocated to three treatment groups: placebo, low dose Iloprost (50–100 g twice
a day) or high dose (150–200 g twice a day)
In Study A the main outcome measures were tolerability of different doses of Iloprost and death, major amputation,
healing of trophic lesions and relief of rest pain at the end of the follow up, which was 5 months after the end of the
treatment. In Study B the primary end point was time to major amputation and stroke or death up to 12 months.
Secondary pre-defined end points included the combined end point of patients alive without amputation, no trophic skin
changes, no rest pain and not on regular analgesics.
Results: the proportion of patients who completed the 4-week treatment period in Study A at the intended dose was
58%, 43%, 45% respectively in the placebo, low dose and high dose Iloprost groups. In an intention to treat analysis the
proportion of patients who survived without major amputation, ulcers or gangrene and had no rest pain was 11% in the
placebo group, 19% in the low dose iloprost group and 28% in the high dose Iloprost group. The pooled Iloprost groups
showed a statistically significantly better result than the placebo group (p=0.04), as did the high dose Iloprost group
compared to the placebo (p=0.014).
In Study B there was no treatment benefit in terms of a primary end point of amputation and death. However the
secondary combined end point of patients who survived without a major amputation, ulcers or gangrene and had no rest
pain, nor a need for regular analgesia was favourable for Iloprost, with 18% of patients in the placebo group reaching
this optimal secondary end point, compared to 23% in the low dose Iloprost group and 26% in the higher dose Iloprost
group (p<0.05).
Conclusions: oral Iloprost administered for a year showed no clear benefit in patients with advanced severe leg ischaemia
(PAOD III and IV). The results obtained with 4 weeks’ treatment in Study A and in previous trials of intravenous
Iloprost could not be reproduced
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Introduction amputation. Patients who have had an attempt at
revascularisation, which has failed, have an even worse
prognosis, with only about half of the patients beingPatients with ulcers, gangrene or rest pain due to
alive with two viable legs after 1 year.1 Although thesevere arterial disease have a poor prognosis, both in
underlying pathology in these patients is major arterialterms of the need for major amputation and mortality.
occlusion, the final pathological results, that is skinTwelve to thirty-two per cent of unselected newly
breakdown or pain, are due to the microcirculatorydiagnosed patients will be dead within the year and
response to a low perfusion pressure. This could the-10% to 20% of the survivors will have required a major
oretically be influenced by pharmacotherapy, for in-
stance prostacyclin and its analogues. These drugs
∗ Please address all correspondence to: J. A. Dormandy, Department
have been widely tested in this indication, initiallyof Vascular Surgery, St. George’s Hospital, Blackshaw Road, London
SW17 0OT, England. administered intra-arterially and more recently intra-
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venously. To our knowledge the present study is the other than Aspirin or patients where revascularisation
or major amputation was planned within the next twofirst to report the results of the effect of an orally active
prostacyclin analogue in this indication. weeks.
Study A was a preliminary pilot study and thereforeSix double-blind placebo-controlled prospective tri-
als of Iloprost, given intravenously, have been pub- the primary end points were tolerability and safety of
four week oral Iloprost treatment. Efficacy end pointslished so far.2–7 Iloprost was given as a daily 6-hourly
infusion in all the trials, with the period of treatment such as major amputation or death at the end of follow
up period, total relief of rest pain without the needvarying from 2–4 weeks. In two trials there was a
formal 6 months’ follow-up period. In all these intra- for analgesics and complete healing of trophic lesions
were secondary end points. In Study B the primaryvenous studies the incidence of death or major am-
putation during the follow-up period was less in the end point of the trial was a combination of time to
any major amputation or death during the 12-monthIloprost group than in the group receiving placebo
and in two of the studies with 6 months’ formal follow- treatment period. Secondary end points were the com-
ponents of the primary end point individually, de-up the difference was statistically significant. The prin-
cipal disadvantage of the Iloprost treatment was that terioration of PAOD necessitating other therapy,
complete lesion healing in patients with trophicit had to be administered in hospital. An orally active
compound would be more practical as these patients changes at baseline and complete relief of rest pain
without regular use of analgesics. There was also awould not need to be hospitalised and treatment could
be continued longer. combined end point defined of patients who were
alive, without a major amputation, with no trophicStudy A was designed primarily to assess the to-
lerablity of two oral dosage regimens over a treatment lesions, no rest pain without regular analgesics. The
studies were approved by the relevant national andperiod of 4 weeks. Encouraged by the apparent efficacy
in this pilot study, Study B was carried out with local ethical committees.
All patients received standard treatment for co-treatment and observation over a year. Because 43%
and 45% of the patients receiving Iloprost in Study A existing disease, pain relief, antibiotics if indicated and
topical therapy for trophic lesions. In both studiescould not complete 4 weeks’ treatment at the intended
dosage, the two doses used in Study A were reduced patients were randomised to three treatment groups:
placebo, low dose Iloprost or high dose Iloprost. Inin Study B from 100 g to 50 g twice a day in the low
dose group, and from 200 g to 150 g twice a day in Study A the low dose group received 100 g twice a
day and the high dose group 200 g twice a day, whilethe higher dose group.
in Study B the low dose group received 50 g twice a
day and the high dose group 150 g twice a day.
The intended dosage of Iloprost was reached after a
Patients and Methods titration period of 5 or 6 days. They were then main-
tained for a total of 28 days in Study A and for 1 year
Study A was conducted in 35 centres in seven countries in Study B. In Study A patients were followed for 6
in Europe (France, Germany, Italy, Norway, Poland, months after the start of the study medication. The
Sweden and Great Britain). Study B was carried out dose could be reduced in both studies at any time if the
in 37 centres in 10 countries (Finland, France, Germany, patient developed unacceptableside effects. In Study B
Great Britain, Hungary, Italy, Norway, Poland, Por- the treatment could also be interrupted temporarily,
tugal and Sweden). for instance while undergoing surgery, and then re-
Patients with trophic skin changes (ulcers or gan- started at a dose level previously tolerated.
grene) or rest pain due to severe arterial disease were
entered; the inclusion criteria in the protocol were
identical in the two studies. Rest pain requiring regular
analgesia had to be present for 2 weeks. Underlying Results
atherosclerosis was established by requiring the
patients to have a maximum ankle systolic Doppler Tables 1a and b show the demographic and baseline
characteristics of the three treatment groups in thepressure of 70 mmHg or less, or a toe systolic pressure
of 50 mmHg or less. The principal exclusion criteria two studies. One hundred and seventy-eight patients
were entered in Study A and 624 patients in Study B.were similar in the two studies: acute onset or rapid
deterioration of the ischaemia, any revascularisation In both studies the entry characteristics of the three
treatment groups were similar, except that in Study Aprocedure in the previous 2 weeks, rapidly spreading
cellulitis, regular treatment with an antiplatelet drug the proportion of diabetics in the placebo group was
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Demographic and baseline characteristics of the treatment groups
Table 1a. Study A
Placebo Iloprost Iloprost
100 g b.i.d. 200 g b.i.d
All patients (n=62) (n=58) (n=58)
Male 37 (60%) 34 (59%) 42 (72%)
Age (mean) (male) 69 71 67
(female) 73 78 73
Diabetic 24 (39%) 18 (31%) 20 (34%)
Smoker 12 (19%) 16 (28%) 14 (24%)
Rest pain only (stage Ill) 13 (21%) 21 (36%) 19 (33%)
Previous vascular intervention 21 (34%) 19 (33%) 23 (40%)
Previous major amputation 8 (13%) 7 (12%) 2 (3%)
Mean ankle systolic pressure 57 mmHg 54 mmHg 63 mmHg
Ankle pressure less than 20 mmHg 13% 12% 7%
Table 1b. Study B
Placebo Low dose Iloprost High dose Iloprost
50 g b.i.d. 150 g b.i.d.
All patients (n=207) (n=210) (n=207)
Male (mean) male 65 66 65
female 75 74 74
Diabetic 57 (28%) 64 (31%) 70 (34%)
Smoker 59 (29%) 61 (29%) 59 (29%)
Rest pain only 95 (46%) 96 (46%) 96 (46%)
(Stage III)
Previous vascular intervention 89 (43%) 92 (44%) 80 (39%)
Previous major amputation 17 (8%) 17 (8%) 18 (9%)
Mean ankle systolic pressure 57 mmHg 54 mmHg 58 mmHg
Ankle pressure less than 20 mmHg 8% 15% 8%
less than in the two Iloprost groups. Comparing the on placebo, 44 on low dose Iloprost and 47 on high
dose Iloprost. During the treatment and follow-uppatients entered as a whole into the two studies,
patients in Study B were approximately 5 years period of 6 months in Study A and one year in Study
B only one and three patients, respectively, were lostyounger than in Study A and there were significantly
more patients with rest pain alone (Stage III). The fact to follow up in terms of primary end points.
Tables 2a and b summarise the efficacy result at thethat these patients were not comparable to the group
of newly diagnosed patients with PAOD III/IV is end of follow-up in the two studies, using an intention-
to-treat analysis. In Study A 48% of the placebo patientsevidenced by the fact that approximately 35% of
patients in Study A and 42% of patients in Study B were dead or had a major amputation by 6 months,
while in Study B the comparable figure was 36%already had a previous vascular intervention. The
remaining patients were either deemed to be un- at 12 months. The efficacy data is also surprisingly
different. In Study A the incidence of major amputationsuitable for revascularisation or were entered into the
study because revascularisation was thought to carry or death, complete pain relief and complete healing
of trophic changes were all in favour both Iloprosta high risk of failure.
In Study A complete discontinuation of treatment groups compared to the placebo. The global efficacy
assessment in terms of number of patients who werewas actually higher in the placebo group (27%) than
in the two Iloprost groups (22%). In Study A dose alive, without a major amputation, with no trophic
changes and no rest pain at the end of the follow upreductions were required in both Iloprost groups. In
the high dose group, intended to receive 200 g per period were 11% in the placebo group compared to
19% in the low dose and 28% in the high dose Iloprostdose, 78% tolerated 100 g or more. However, in the
low dose group, who were intended to receive 100 g groups. The difference between the pooled Iloprost
groups and the placebo group was statistically sig-per dose, only 43% of the patients could tolerate this.
It was for this reason that both the high and low dose nificant (p=0.04) as well as the difference between the
high dose Iloprost and the placebo groups (p=0.01).doses of Iloprost were reduced in Study B. In Study
B, where treatment was continued for a year, it had It was this favourable result in Study A, which was
not powered to look at efficacy, which encouraged theto be discontinued for adverse events in 39 patients
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Table 2a. Efficacy results at 6 months in Study A.
Placebo Iloprost Iloprost
100 g b.i.d. 200 g b.i.d.
All patients (n=62) (n=58) (n=58)
Major amputation 20 (32%) 14 (24%) 15 (26%)
Death 12 (19%) 8 (14%) 6 (10%)
Major amputation or death 30 (48%) 20 (34%) 19 (33%)
Alive, without major amputation, no ulcer 7 (11%) 11 (19%) 16 (28%)
or gangrene and no rest pain∗
Stage III (n=13) (n=21) (n=19)
Complete pain relief∗ 4 (31%) 7 (33%) 9 (47%)
Stage IV (n=49) (n=37) (n=39)
Complete healing of ulcers and gangrene 6 (12%) 7 (19%) 10 (26%)
Table 2b. Efficacy results at the end of 12 months’ treatment in Study B.
Event Placebo Low dose Iloprost High dose Iloprost
50 g b.i.d. 150 g b.i.d.
All patients (n=207) (n=210) (n=207)
Major amputation 61 (30%) 55 (26%) 52 (25%)
Death 25 (12%) 23 (11%) 32 (16%)
Major amputation or death 74 (36%) 71 (34%) 72 (35%)
Alive, without major amputation, no skin lesions, 37 (18%) 49 (23%) 54 (26%)
no pain∗
Stage III (n=95) (n=95) (n=96)
Complete relief of rest pain∗ 23 (24%) 26 (27%) 34 (39%)
Stage IV patients (n=112) (n=114) (n=111)
Complete healing of ulcers and gangrene 22 (20%) 34 (30%) 27 (24%)
∗Counting patients with no rest pain and no regular analgesics use, alive without major amputation.
investigators to proceed to a larger Study B with a 1- but the results suggest that titrating the dose over the
year treatment and observation period. Unfortunately first few days results in better compliance with the
the beneficial trends seen in Study A were not re- higher doses. Both studies also suggest that incidence
produced. There was no difference between the three of side effects declined rapidly over the first few weeks.
groups in the primary end point of major amputation The relatively high healing rates in both studies in
and/or death. Explorative univariate subgroup ana- patients with trophic changes, both in the Iloprost and
lyses of patients with Stage III or Stage IV, diabetic or in the placebo groups, was probably due to all patients
non diabetic, ankle systolic pressure above or below receiving standard care, including treatment of pre-
20 mmHg at entry did not reveal a clear difference existing cardiac disease and the local treatment to
from the overall result in any of the subgroups when trophic lesions.
analysed for the primary end point. In the pre-specified Six double-blind placebo controlled studies2–7 of Ilo-
combined secondary end point of patients alive, with- prost given intravenously for up to 4 weeks have been
out a major amputation, with no trophic lesions, no rest published so far in a total of 740 patients with severe
pain and no regular use of analgesics. The difference leg ischaemia causing trophic changes or rest pain.
between the three groups was significant (p<0.05). 18% Two hundred and seventy patients participated in two
of patients in the placebo group reached this optimal trials where there was a prospective follow-up of
secondary end point, compared to 23% in the low dose 6 months. Both trials showed statistically significant
Iloprost group and 26% in the higher dose Iloprost reduction in major amputation or death at 6 months
group. in favour of the Iloprost groups. The pooled ITT results
from these two trials, including additional retro-
spectively collected follow-up information from the
other trials, showed the incidence of major amputationDiscussion
and/or death in the placebo group was 57% compared
to 40% in the Iloprost groups. It therefore seemedDiscontinuation due to side effects did not differ sig-
nificantly between the Iloprost and placebo groups, reasonable to proceed to a similar study when an oral
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lower limb. A Scandinavian–Polish placebo-controlled, ran-formulation of Iloprost became available. As far as we
domized multicenter study. Eur J Vas Surg 1990; 4: 463–467.are aware, these are the first reports of studies an oral 6 Guilmot JL, Diot B, Dormandy J et al. Treatment of lower limb
ischaemia due to atherosclerosis in diabetic and non diabeticformulation of a prostacyclin analogue in a prospective
patients with Iloprost, a stable analogue of prostacyclin: resultsdouble-blind placebo-controlled study in patients with
of the French multicenter trial. Drug Invest 1991: 3: 351–359.severe leg ischaemia. In the smaller Study A on an 7 Balzer K, Bechara G, Bisler H et al. Reduction of ischaemic
rest pain in advanced peripheral arterial occlusive disease – aintention to treat analysis, the incidence of major am-
double blind placebo controlled trial with Iloprost. Int Angiolputation and/or death in the placebo group was 48%,
1991; 10: 22–32.slightly less than in the previous intravenous studies.
However the advantage in favour of Iloprost was very Accepted 13 June 2000
similar in the 4-week intravenous trials and the 4-
week oral Study A. The results of the larger Study B,
where oral Iloprost was given for a year, could not Addendum
however reproduce similar differences in amputation
and/or death rate between placebo and the treated Steering committees
groups. Both studies, however, were statistically sig-
nificant in favour of Iloprost in terms of one predefined H. Boccalon (France), A. Braga (Portugal), K. Breddin
secondary end point, that is patients alive without an (Germany), H. Catalano (Italy), J. Dormandy (Great
amputation, no trophic changes, no rest pain and not Britain, Chairman), L. Norgren (Sweden), S. Lopaciuk
requiring regular analgesia. This end point could be (Poland).
said to represent the optimal short to medium term
outcome for these patients. However, as the primary
end point in the larger Study B failed to show a
Contributing centresstatistically significant effect, the overall results should
be interpreted with great caution.
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